Johnson & Johnson (NYSE:JNJ) reported on Monday that its board of directors approved a common stock cash dividend of USD0.95 per share for the third quarter of 2019,the company .
With an ex-dividend date of 26 August 2019, the dividend will be paid on 10 September 2019 to shareholders of record at the close of business on 27 August 2019.
Johnson & Johnson together with its subsidiaries, researches and develops, manufactures and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical and Medical Devices.
The company was incorporated in 1887 and is based in New Brunswick, New Jersey, USA.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return